Evidence map›Paper›PMID 31174485›Full record

ArticleBMC cancer2019

Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.

Mariana Bustamante Eduardo, Vlad Popovici, Sara Imboden, Stefan Aebi, Nadja Ballabio, Hans Jörg Altermatt, Andreas Günthert, Rolf Jaggi

Abstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mariana Bustamante EduardoDepartment for Biomedical Research, University of Bern, Murtenstrasse, 40, 3008, Bern, Switzerland.
Vlad PopoviciRECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
Sara ImbodenDepartment of Gynecology and Obstetrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Stefan AebiDepartment of Medical Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Nadja BallabioBreast Center Unit at gyn-zentrum, Lucerne, Switzerland.
Hans Jörg Altermattconsultarif DRG, Lohn-Ammannsegg, Switzerland.
Andreas GünthertBreast Center Unit at gyn-zentrum, Lucerne, Switzerland.
Rolf JaggiDepartment for Biomedical Research, University of Bern, Murtenstrasse, 40, 3008, Bern, Switzerland. rolf.jaggi@dbmr.unibe.ch.ORCID http://orcid.org/0000-0002-5975-9607

Funding

RECETOX Research Infrastructure LM2015051 and CZ.02.1.01/0.0/0.0/16_013/0001761
6 · The paper itself

Abstract

backgroundBreast cancer is a leading cause of cancer-related death in women worldwide. Despite extensive studies in all areas of basic, clinical and applied research, accurate prognosis remains elusive, thus leading to overtreatment of many patients. Diagnosis could be improved by introducing multigene molecular scores in standard clinical practice. Several tests that work with formalin-fixed tissue have become routine. Molecular scores usually include several genes representing processes, response to oestrogens, progestogens and human epidermal growth factor receptor 2 (Her2), respectively, which are combined additively in single values. These multi-gene scores have the advantage of being more robust and reproducible than single-gene scores. Their utility may be further enhanced by combining them with classical diagnostic parameters. Here, we present an exploratory study comparing the RISK and research versions of Oncotype DX recurrence score (RS), Prosigna Risk of Recurrence (ROR) and EndoPredict (EP) with respect to their prognostic potential for ipsilateral recurrence and/or distant relapse in brain, and we compared the scores to the intrinsic subtypes based on PAM50.

methodsRNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue cores of primary tumours, local recurrences and brain metastases. Gene expression was measured on a NanoString nCounter Analysis System. Intrinsic subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2↑), Basal-like (basal), and Normal-like (normal) of PAM50. Local recurrences and brain metastases were compared to their corresponding primary tumours.

resultsAll four molecular scores were highly correlated. Highest correlations were observed among genes related to proliferation while lower correlations were found among oestrogen-related genes. The scores were significantly higher in primary tumours progressing to brain metastases as compared to recurrence-free primary tumours and primary tumours that relapsed as local recurrences.

conclusionsRISK and ROR-P are prognostic for primary tumours metastasizing to the brain. All four scores, RISK, RS, EP and ROR-P failed to discriminate between primary tumours that remained recurrence-free and primary tumours relapsing as local recurrences.

Indexed as

TranscriptomeAdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsComputational BiologyFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedNeoplasm GradingBiomarkers, TumorBrain metastasisBreast cancerGene expression measurementHierarchical clusteringImmunohistochemistryLocal recurrenceMolecular risk scoresPAM50 subtypesRNA isolation and processing

Identifiers

PMID31174485
PMCPMC6556009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.